Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2397314 | 0.96 | — | — | |
| SCHEMBL26993337 | 0.96 | — | — | |
| Formic Acid SCHEMBL30940231 | 0.77 | — | — | |
| SCHEMBL4203534 | 0.75 | — | — | |
| SCHEMBL4821993 | 0.75 | — | — | |
| SCHEMBL25819484 | 0.75 | — | — | |
| Hydrochloric Acid SCHEMBL31438346 | 0.74 | — | — | |
| Hydrochloric Acid SCHEMBL22492199 | 0.74 | — | — | |
| Hydrochloric Acid SCHEMBL15671602 | 0.72 | — | — | |
| Hydrochloric Acid SCHEMBL17867592 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12577228-B2 | Dihydrocyclopenta-isoquinoline-sulfonamide derivatives compounds | UCB Biopharma SRL (BE) | 2026-03-17 | — | — | US | disclosed |
| EP-4081296-B1 | DIHYDROCYCLOPENTA-ISOQUINOLINE-SULFONAMIDE DERIVATIVES COMPOUNDS | UCB Biopharma SRL (BE) | 2026-02-11 | — | — | EP | disclosed |
| EP-4267566-A1 | 2H-INDAZOLE DERIVATIVES AS IRAK4 INHIBITORS AND THEIR USE IN THE TREATMENT OF DISEASE | Biogen MA Inc. (US) | 2023-11-01 | — | — | EP | disclosed |
| CN-116940572-A | 2H-indazole derivatives as IRAK4 inhibitors and their use in the treatment of diseases | 渤健马萨诸塞州股份有限公司 | 2023-10-24 | — | — | CN | disclosed |
| CN-116867781-A | Imidazo [1,2-a ] pyridine derivatives as IRAK4 inhibitors and their use in the treatment of diseases | 渤健马萨诸塞州股份有限公司 | 2023-10-10 | — | — | CN | disclosed |
| US-20230303517-A1 | DIHYDROCYCLOPENTA-ISOQUINOLINE-SULFONAMIDE DERIVATIVES COMPOUNDS | UCB BIOPHARMA SRL (SOCIETE A RESPONSABILITE LIMITEE) (GB) | 2023-09-28 | — | — | US | disclosed |
| EP-4081296-A1 | DIHYDROCYCLOPENTA-ISOQUINOLINE-SULFONAMIDE DERIVATIVES COMPOUNDS | UCB Biopharma SRL (BE) | 2022-11-02 | — | — | EP | disclosed |
| CN-114845778-A | Dihydrocyclopentaisoquinoline sulfonamide derivative compound | UCB生物制药有限责任公司 | 2022-08-02 | — | — | CN | disclosed |
| WO-2022140415-A1 | 2H-INDAZOLE DERIVATIVES AS IRAK4 INHIBITORS AND THEIR USE IN THE TREATMENT OF DISEASE | BIOGEN MA INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| WO-2021130259-A1 | DIHYDROCYCLOPENTA-ISOQUINOLINE-SULFONAMIDE DERIVATIVES COMPOUNDS | UCB Biopharma SRL (BE) | 2021-07-01 | — | — | WO | disclosed |
| CN-105001226-B | Tricyclic heterocyclic compounds and JAK inhibitor | 日产化学工业株式会社 | 2017-09-08 | — | — | CN | disclosed |
| US-9556187-B2 | Substituted pyrrolo[3′,2′:5,6]pyrido[4,3-d]pyrimidines and JAK inhibitors comprising the same | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2017-01-31 | — | — | US | disclosed |
| EP-3112370-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AND JAK INHIBITORS | Nissan Chemical Industries, Ltd. (JP) | 2017-01-04 | — | — | EP | disclosed |
| US-20160102102-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AND JAK INHIBITORS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-04-14 | — | — | US | disclosed |
| US-9216999-B2 | Substituted pyrrolo[2,3-h][1,6]naphthyridines and compositions thereof as JAK inhibitors | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2015-12-22 | — | — | US | disclosed |
| CN-105001226-A | Tricycle heterocyclic compounds and JAK inhibitors | NISSAN CHEMICAL IND LTD | 2015-10-28 | — | — | CN | disclosed |
| EP-2742049-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AND JAK INHIBITORS | Nissan Chemical Industries, Ltd. (JP) | 2014-06-18 | — | — | EP | disclosed |
| CN-103732597-A | Tricyclic heterocyclic compounds and JAK inhibitors | NISSAN CHEMICAL IND LTD | 2014-04-16 | — | — | CN | disclosed |
| WO-2013024895-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AND JAK INHIBITORS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2013-02-21 | — | — | WO | disclosed |